BofA raised the firm’s price target on Krystal Biotech to $168 from $140 and keeps a Buy rating on the shares. The company’s “big beat” in Q4 was “a much-needed and well-timed rebound after the narrow sales miss” in Q3, says the analyst, who sees Q4 earnings effectively addressing investor concerns regarding the launch trajectory for Vyjuvek.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on KRYS:
- New Sales & Marketing Risk for Krystal Biotech, Inc. – What’s the Latest?
- Krystal Biotech sees 2024 non-GAAP R&D, SG&A expense $150M-$175M
- Krystal Biotech reports Q4 EPS 30c, consensus (38c)
- Krystal Biotech, Inc. (KRYS) Q4 Earnings Cheat Sheet
- Krystal Biotech to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024
